Terumo Yönetim

Yönetim kriter kontrolleri 1/4

Terumo CEO'su Hikaru Samejima, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.003% doğrudan sahiptir ve bu hisselerin değeri $ 794.06K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 3.1 yıldır.

Anahtar bilgiler

Hikaru Samejima

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.003%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Hikaru Samejima (60 yo)

less than a year

Görev süresi

Mr. Hikaru Samejima served as Director of Terumo Corporation since February 7, 2024 until June 26, 2024 and serves as its Representative Director since June 26, 2024. He serves as President and CEO of Teru...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	14.4yrs	JP¥137.00m	Veri yok
Hikaru Samejima	Representative Director	less than a year	Veri yok	0.0027% $ 794.1k
Jin Hagimoto	CFO, CIO	less than a year	Veri yok	Veri yok
Shinji Omori	CTO, GM of DX Promotion Dept. R&D Division and Executive Officer	less than a year	Veri yok	Veri yok
Miho Mizuguchi	Executive Officer	8.6yrs	Veri yok	Veri yok
Tomoko Adachi	Chief Human Resources Officer & Group Executive Officer	1.8yrs	Veri yok	Veri yok
Kazunori Hirose	Director & Group Managing Executive Officer	no data	Veri yok	0.0023% $ 674.7k
Itaru Sakaguchi	Group Managing Executive Officer	less than a year	Veri yok	Veri yok
Toshihiko Osada	Group Senior Managing Executive Officer & Director	no data	Veri yok	Veri yok
Fumihisa Hirose	Group Managing Executive Officer	less than a year	Veri yok	Veri yok
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.6yrs	Veri yok	0.0026% $ 782.1k
Antoinette Gawin	Group Senior Managing Executive Officer	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim: TRUM.Y 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	14.4yrs	JP¥137.00m	Veri yok
Hikaru Samejima	Representative Director	less than a year	Veri yok	0.0027% $ 794.1k
Kazunori Hirose	Director & Group Managing Executive Officer	2.8yrs	Veri yok	0.0023% $ 674.7k
Toshihiko Osada	Group Senior Managing Executive Officer & Director	less than a year	Veri yok	Veri yok
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.4yrs	Veri yok	0.0026% $ 782.1k
Soichiro Uno	Independent Director	5.4yrs	Veri yok	Veri yok
Hidenori Nishi	Independent Outside Director	4.4yrs	Veri yok	0.00029% $ 86.6k
Takanori Shibazaki	Director	3.4yrs	Veri yok	0.0025% $ 737.3k
Koichi Sakaguchi	Substitute Director	2.4yrs	Veri yok	Veri yok
Masaichi Nakamura	Independent Outside Director	5.4yrs	Veri yok	0.00037% $ 110.5k
Keiya Ozawa	Independent Outside Director	3.4yrs	Veri yok	0.00011% $ 32.8k
Mari Kogiso	Independent Director	less than a year	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TRUM.Y 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Terumo Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Recent updates

Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022

Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc.

Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd

Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021

Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020

Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.

Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.

Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş